Journal of Cancer Research and Clinical Oncology · 18 authors, 13 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In a retrospective real-world cohort of 184 thyroid cancer patients from five referral centers, 4% harbored NTRK gene fusions. Six patients with NTRK fusion-positive radioiodine-refractory disease treated with larotrectinib achieved an 83% objective response rate with a favorable safety profile.
A retrospective, multicenter study across five German and Austrian referral centers tested 184 thyroid cancer patients for NTRK gene fusions, identifying eight (4%) fusion-positive cases. Six patients with radioiodine-refractory disease harboring NTRK1 (n=4) or NTRK3 (n=2) fusions were treated with larotrectinib, five of whom had received at least one prior systemic therapy. All patients had morphologically progressive disease before treatment. The objective response rate was 83%, including two complete remissions, with median progression-free survival of 23 months and median overall survival not reached. Adverse events were grade 1–3, with weight gain (33%) and fatigue (33%) most common; one patient discontinued due to treatment-emergent adverse events. Limitations include the retrospective design, small sample size, lack of systematic follow-up, heterogeneity of patient management, and imaging evaluation by different radiologists.
